FOLD
Price:
$11.65
Market Cap:
$3.46B
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on t...[Read more]
Industry
Biotechnology
IPO Date
2007-05-31
Stock Exchange
NASDAQ
Ticker
FOLD
According to Amicus Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.69B. This represents a change of -2.62% compared to the average of 3.79B of the last 4 quarters.
The mean historical Enterprise Value of Amicus Therapeutics, Inc. over the last ten years is 2.68B. The current 3.69B Enterprise Value has changed 13.65% with respect to the historical average. Over the past ten years (40 quarters), FOLD's Enterprise Value was at its highest in in the December 2020 quarter at 6.26B. The Enterprise Value was at its lowest in in the September 2014 quarter at 464.02M.
Average
2.68B
Median
2.37B
Minimum
609.65M
Maximum
6.26B
Discovering the peaks and valleys of Amicus Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 567.34%
Maximum Annual Enterprise Value = 6.26B
Minimum Annual Increase = -46.77%
Minimum Annual Enterprise Value = 609.65M
Year | Enterprise Value | Change |
---|---|---|
2023 | 4.39B | 14.45% |
2022 | 3.83B | 15.10% |
2021 | 3.33B | -46.77% |
2020 | 6.26B | 159.67% |
2019 | 2.41B | 19.15% |
2018 | 2.02B | -12.93% |
2017 | 2.32B | 265.46% |
2016 | 635.41M | -38.81% |
2015 | 1.04B | 70.32% |
2014 | 609.65M | 567.34% |
The current Enterprise Value of Amicus Therapeutics, Inc. (FOLD) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
3.85B
5-year avg
4.04B
10-year avg
2.68B
Amicus Therapeutics, Inc.’s Enterprise Value is less than Incyte Corporation (10.85B), greater than Denali Therapeutics Inc. (3.59B), less than argenx SE (31.01B), greater than Harmony Biosciences Holdings, Inc. (1.92B), less than Ultragenyx Pharmaceutical Inc. (5.53B), less than Crinetics Pharmaceuticals, Inc. (3.78B), greater than Arvinas, Inc. (1.52B), less than Revolution Medicines, Inc. (6.80B), greater than Kura Oncology, Inc. (1.45B), greater than Mineralys Therapeutics, Inc. (490.57M), less than Legend Biotech Corporation (10.04B), less than Cytokinetics, Incorporated (6.96B), greater than Inhibrx, Inc. (-6681886.00), greater than DICE Therapeutics, Inc. (2.21B), greater than Edgewise Therapeutics, Inc. (1.60B), less than Karuna Therapeutics, Inc. (12.43B), greater than Dyne Therapeutics, Inc. (2.73B), greater than Mereo BioPharma Group plc (582.99M), less than Blueprint Medicines Corporation (6.16B), greater than Agios Pharmaceuticals, Inc. (2.44B), greater than Day One Biopharmaceuticals, Inc. (1.01B), less than BioMarin Pharmaceutical Inc. (16.13B),
Company | Enterprise Value | Market cap |
---|---|---|
10.85B | $11.80B | |
3.59B | $3.61B | |
31.01B | $32.41B | |
1.92B | $2.02B | |
5.53B | $5.09B | |
3.78B | $4.03B | |
1.52B | $1.68B | |
6.80B | $6.99B | |
1.45B | $1.48B | |
490.57M | $558.43M | |
10.04B | $9.90B | |
6.96B | $6.36B | |
-6681886.00 | $218.01M | |
2.21B | $2.27B | |
1.60B | $1.64B | |
12.43B | $12.60B | |
2.73B | $3.32B | |
582.99M | $664.26M | |
6.16B | $5.47B | |
2.44B | $2.46B | |
1.01B | $1.25B | |
16.13B | $16.01B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Amicus Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Amicus Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Amicus Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Amicus Therapeutics, Inc. (FOLD)?
What is the 3-year average Enterprise Value for Amicus Therapeutics, Inc. (FOLD)?
What is the 5-year average Enterprise Value for Amicus Therapeutics, Inc. (FOLD)?
How does the current Enterprise Value for Amicus Therapeutics, Inc. (FOLD) compare to its historical average?